The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus : principal results of the Diabetic Atherosclerosis Prevention by Cilostazol(DAPC)study : a randomized trial
Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study
Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: a randomized controlled trial
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22
Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO):a multicentre, randomised controlled trial
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)
High-density lipoproteins from probucoltreated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins
High-density lipoprotein, but not lowdensity lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial
Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST)
Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty : the Probucol Angioplasty Restenosis Trial
Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and MCSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis
Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats
